Virobay Gets $8M In Additional Series B

Menlo Park-based Virobay, which is developing pharmaceuticals to treat neuropathic pain, autoimmune disease and fibrosis, has raised $8M in an additional, Series B funding. The funding came from Perceptive Advisors, as well as existing investors TPG Biotechnology Partners, Alta Partners, Sutter Hill Ventures and Abbvie. The company said the second tranche of its Series B brings its total funding in its Series B to $18M. Virobay is led by Dr. Robert Booth. More information »